Adaptive Biotechnologies (ADPT) EV to CFO (2019 - 2026)

Adaptive Biotechnologies has disclosed EV to CFO across 8 years of filings, most recently posting 480.52 for Q2 2026.

• In Q2 2026, EV to CFO fell 279.11% year-over-year to 480.52; the TTM figure through Jun 2026 stood at 146.38 (down 647.66% YoY), while the FY2025 annual figure was 49.51, down 611.33% from the prior year.
• EV to CFO came in at 480.52 for Q2 2026 at Adaptive Biotechnologies, down from 210.36 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 1107.84 in Q4 2025 to a low of 480.52 in Q2 2026.
• Average EV to CFO over 5 years is 14.25, with a median of 19.37 recorded in 2022.
• The largest YoY upside for EV to CFO was 2188.29% in 2025 against a maximum downside of 1435.12% in 2025.
• Over 5 years, EV to CFO stood at 19.82 in 2022, then surged by 31.75% to 13.53 in 2023, then slumped by 292.1% to 53.05 in 2024, then jumped by 2188.29% to 1107.84 in 2025, then plunged by 143.37% to 480.52 in 2026.
• Per Business Quant data, the three most recent EV to CFO figures were 480.52 in Q2 2026, 210.36 in Q1 2026, and 1107.84 in Q4 2025.